Spontaneous regression of neoplasms: new possibilities for immunotherapy

Bibliography

• MARSHALL C: Tumor suppressor genes. Cell, (1991) 64:313–326.
   PubMed Web of Science ®Google Scholar
• ••Nice review article about the significanceof TSGs.
   Google Scholar
• BODEY B, KAISER HE, GOLD FARB RH,: Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Anticancer Res. (1996) 16:517–531.
   Google Scholar
• •Detailed irnmunocytochemical characterisation of subpopulations of continuous IP changes in melanoma cells.
   Google Scholar
• BODEY B, GROGER AM, BODEY B JR, SIEGEL SE, KAISER HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res. (1997) 17:493–498.
   PubMed Web of Science ®Google Scholar
• HEDRICK L, CHO KR, FEARON ER,WU T-C, KINZLER KW, VOGELSTEIN B: The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev. (1994) 8:1174–1183.
   PubMed Web of Science ®Google Scholar
• PERRY ME, LEVINE AJ: P53 and mdm-2: interactions between tumor suppressor gene and oncogene products. Mount Sinai J. Med. (1994) 61:291–299.
   PubMed Web of Science ®Google Scholar
• TALIB VH, PANDEY J, DHUPIA JS: Molecular markers in cancer diagnosis. Ind. Pathol. Microbial. (1995) 38:1–3.
   PubMedGoogle Scholar
• ••Important description of neoplasm-associated antigens.
   Google Scholar
• JACOBSON DR, FISHMAN CL, MILLS NE: Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Ann. Oncol. (1995) 6:S3–S8.
   PubMedGoogle Scholar
• BUGERT P, KOVACS G: Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am. J. Pathol,. (1996) 149:2081–2088.
   PubMed Web of Science ®Google Scholar
• DIETZMANN K, VON BOSSANYI P, SALLABA J, KIRCHES E, SYNOWITZ HJ, WARICH-KIRCHES M: Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation. Gen. Diagn. Pathol. (1996) 141:339–344.
   PubMedGoogle Scholar
• VOLPE JP: Genetic instability of cancer: why a metastatic tumor is unstable and a benign tumor is stable. Cancer Genet. Cytogenet. (1988) 34:124–134.
   Google Scholar
• ••The genetic instability of neoplastically transformed, cells is crucial during a systematic neoplastic disease.
   Google Scholar
• BODEY B, ZELTZER PM, SALDIVAR V, KEMSHEAD J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. hat. J. Cancer (1990) 45:1079–1087.
   PubMed Web of Science ®Google Scholar
• BODEY B, BODEY B JR, GROGER AM, SIEGEL SE, KAISER HE: Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors. Anticancer Res. (1997) 17:189–196.
   PubMed Web of Science ®Google Scholar
• BODEY B, BODEY B JR, GROGER AM, SIEGEL SE, KAISER HE: Nm23/ nucleoside diphosphate (NDP) kinase expression in human malignant melanomas. Significance and implications in tumor biology. Anticancer Res. (1997) 17:505–512.
   Google Scholar
• VOGELSTEIN B, FEARON E, HAMILTON, SR et al.: Genetic alterations during colorectal-tumor development. N Engl. J. Med. (1988) 319:525–532.
   PubMed Web of Science ®Google Scholar
• ••Significant paper from one of the pioneersof genetic observations in colorectal cancer.
   Google Scholar
• SIRICA AE: Multistage carcinogenesis incellular and molecular pathogenesis. Lippincott-Raven, Philadelphia (1996)283–320.
   Google Scholar
• POLLLARD M, LUCKERT PH: Phenobarbital promotes multistage pulmonary carcinogenesis in MNU- inoculated, L-W rats. In Vivo (1997) 11:55–60.
   PubMed Web of Science ®Google Scholar
• NICOLSON GL: Growth mechanism and cancer progression. Hosp. Prac. (1993) 28:43–53.
   Web of Science ®Google Scholar
• PARSONS DF: Some tumor cell protein kinases activated by receptors as markers, including elastin receptors. Cancer Invest. (1995) 13:629–636.
   PubMed Web of Science ®Google Scholar
• PAPAC RJ: Spontaneous regression of cancer. Cancer Treat. Rev. (1996) 22:395–423.
   PubMed Web of Science ®Google Scholar
• ••Excellent review about SR.
   Google Scholar
• BOYD W: The Spontaneous Regression of Cancer. Charles C Thomas Publications, Springfield, USA (1966).
   Google Scholar
• ••A monograph about the SR of humanneoplasms.
   Google Scholar
• MEARES M: Regression of cancer after intensive meditation. Med. J. Austr. (1976) 5:184.
   Google Scholar
• MEARES M: Regression of osteogenic sarcoma metastases associated with intensive meditation. Med. J. Austr. (1978) 2:433.
   PubMed Web of Science ®Google Scholar
• BENNETT WH: Some peculiarities in thebehavior of certain malignant and innocent growths. Lancet (1899) 1:3–7.
   Google Scholar
• RHODENBERG GL: Fluctuations in the growth rate of malignant tumors in man, with special reference to spontaneous regression. Cancer Res. (1918) 3:193–221
   Google Scholar
• CUSHING H, WOLLBACH SB: The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am. J. Pathol. (1927) 3:203–216.
   PubMedGoogle Scholar
• •Early work about the spontaneous change of cellular IP.
   Google Scholar
• BUMPUS HC JR: The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. Urol. (1928) 20:185–191.
   Google Scholar
• EVERSON TC, COLE WH: Spontaneous Regression of Cancer. WB Saunders, Philadelphia (1966):1–1187.
   Google Scholar
• ••Detailed report about the SR.
   Google Scholar
• CHALLIS GB, STAM HJ: The spontaneous, regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. (1990) 29:545–550.
   Google Scholar
• •Short review of 87 years of SR experience.
   Google Scholar
• O'REGAN B, HIRSCHBERG C: Spontaneous Remission - an Annotated Bibliography Sausalito (ed.), Institute of Noetic Sciences, California (1993).
   Google Scholar
• ••An important bibliography of submittedcases of SR.
   Google Scholar
• OSLER W: The medical aspects of carcinoma of the breast, with a note on the spontaneous disappearance of secondary growths. Am. Med. (1901) 17–19:63–66.
   Google Scholar
• RAE MV: Spontaneous regression of hypernephroma. Am. Cancer (1935) 24:839–841.
   Google Scholar
• COLE WH: Spontaneous regression of cancer. The metabolic triumph of the host? Ann. NY Acad. Sci. (1974) 230:111–141.
   PubMed Web of Science ®Google Scholar
• PAPAC RJ: Spontaneous regression of cancer. Conn. Med. (1990) 54:179–182.
   PubMedGoogle Scholar
• KAISER HE: A biological approach to an understanding of regression. In: Cancer Growth and Progression (Vol. 4). Influence of Tumor Development of the Host Progression. Kaiser HE, Herberman RB (eds), Kluwer Academic Publishers, Dordrecht, The Netherlands (1989):42.
   Google Scholar
• KAISER HE: Biological viewpoints of neoplastic regression. In Vivo (1994) 8:155–165.
   PubMedGoogle Scholar
• COOPER KR: Regression of neoplasms in invertebrates with special emphasis on mollusca. In: Cancer Growth and Progression (Vol. 4). Influence of Tumor Development of the Host Kaiser HE, Herberman RB (eds), Kluwer Academic Publishers, Dordrecht, The Netherlands (1989):30–36.
   Google Scholar
• MEINS F JR: Tumor reversal and tumor suppression in plants. In: Cancer Growth and Progression (Vol. 4). Influence of Tumor Development of the Host. Kaiser HE, Herberman RB (eds), Kluwer Academic Publishers, Dordrecht, The Netherlands (1989):37–41.
   Google Scholar
• XYLANDER WER: Immune defense in arthropods - how chelicerates, crustaceans, insects and myriapods protect themselves against disease. Spiegel der Forschung(1994) 11:27–30.
   Google Scholar
• KRUSE J: Spontaneous remission of breastcancer. Ugeskr: Laeger (1999) 161:4001–4004.
   PubMedGoogle Scholar
• SHARMA DN, MOHANTI BK, SHUKLA, NK, PATH GK: Spontaneous regression of carcinoma of the stomach. Clin. Oncol (R. Coll Radio].) (2000) 12:335–336.
   PubMed Web of Science ®Google Scholar
• MURAI Y, KOBAYASHI S, MIZUNARI T, OHAKI Y, ADACHI K, TERAMOTO A: Spontaneous regression of a germinoma in the pineal body after placement of a ventriculoperitoneal shunt. Neurosurg. (2000) 93:884–886.
   Web of Science ®Google Scholar
• OKADA S, ABO T: Spontaneous regression of hepatocellular carcinoma. Gastroenterol. Hepatol. (2000) 15(9):965–966. Comment in: Gastroenterol. Hepatol. (2000) 15(9):1079–1086.
   Google Scholar
• UENISHI T, HIROHASHI K, TANAKA H, IKEBE T, KINOSHITA H: Spontaneous regression of a large hepatocellular carcinoma with portal vein tumor thrombi: report of a case. Surg. Today (2000) 30:82–85.
   PubMed Web of Science ®Google Scholar
• GALLUCCI M, CATALUCCI A, SCHEITHAUER BW, FORBES GS: Spontaneous involution of pilocytic astrocytoma in a patient without neurofibromatosis Type 1: case report. Radiology (2000) 214(1):223–226.
   PubMed Web of Science ®Google Scholar
• BARIOL C, FIELD A, VICKERS CR, WARD R: Regression of gastric T cell lymphoma with eradication of Helicobacter pylori. Gut (2001) 48:269–271.
   PubMed Web of Science ®Google Scholar
• Le MEUR Y, PONTOIZEAU- POTELUNE, N, JACCARD A, PARAF F, LEROUX-ROBERT C: Regression of a gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pyloriin a kidney graft recipient. Am.). Med. (1999) 107:530.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB M, KAPLINSKY C, AMARIGLIO N, ROSNER E, BROK-SIMONI F, RECHAVI G: Spontaneous regression of congenital leukaemia with an 8;16 translocation. Br.j Haematol (2000) 111(2):641–643.
   PubMed Web of Science ®Google Scholar
• ••Genetic observation that would allow forthe proper decision to be made as to whether or not to apply antineoplastic treatment.
   Google Scholar
• CHOUDHARI KA, McLORINAN GC, BYRNES DP: Spontaneous regression of a primary cerebral tumour following postoperative middle cerebral artery territory infarction. Br. Neurosurg. (2001) 15(2):177–179 (Discussion 179–180)
   Google Scholar
• PARKER R, LAN VIN D, GILKS B, MILLER D: Spontaneous regression of stage IV clear cell carcinoma of the endometrium, in a patient with essential thrombocytosis. Gynecol. Oncol (2001) 82:395–399.
   PubMed Web of Science ®Google Scholar
• PRINTZ C. Spontaneous regression of melanoma may offer insight into cancer immunology. Nati Cancer Inst. (2001) 93(14):1047–1048.
   PubMed Web of Science ®Google Scholar
• ••SR reported in melanoma.
   Google Scholar
• WELLS H: Chemical Pathology WB Saunders, Philadelphia (1925).
   Google Scholar
• GLUMAC G, MATES A, EIDINGER D: The heterocytotoxicity of human serum. III. Studies of the serum levels and distribution of activity in human populations. Clin. Exp. Immunol (1976) 26:601–608.
   PubMed Web of Science ®Google Scholar
• HELLSTROM KE, HELLSTROM I: Spontaneous tumor regression: possible relationships to in vitro parameters of tumor immunity. Nati Cancer. Inst. Monogr: (1976) 44:131–134.
   Google Scholar
• BOLANDE RP, TODD EW: The cytotoidc action of normal human serum on certain cells propagated in vitro. AMA Arch. Pathol (1958) 66:720–732.
   PubMedGoogle Scholar
• BOLANDE RP: Spontaneous regression of neuroblastoma: an experimental approach. Ped. Pathol. (1990) 10:195–206.
   PubMedGoogle Scholar
• GROSS J, SIMON E, SZWARC-BILOTYNSKI L, DURST A, PFEFFERMAN R, POLISHUK Z: Complement-dependent lysis of Ehrlich ascites cells by human serum (ascitolysin) is lowered in cancer patients and raised in pregnant women. Eur: J. Cancer Clin. Oncol. (1986) 22:13–19.
   PubMedGoogle Scholar
• BOLANDE RP, ARNOLD JL, MAYER DC: Natural cytotoxicity of human serum. A natural IgM 'antibody' sensitizes transformed murine cells to the lytic action of complement. Pathol Immunopathol. Res. (1989) 8:46–60.
   Google Scholar
• EVANS AE, GERSON J, SCHNAUFER L: Spontaneous remission of neuroblastoma. Nati Cancer Inst. Monogr. (1976) 44:49–54.
   Google Scholar
• CHEUNG NK, SAARINEN UM, NEELY JE, LANDMEIER B, DONOVAN D, COCCIA PF: Monoclonal antibodies to a glycolipid antigen of human neuroblastoma cells. Cancer Res. (1985) 45:2642–2649.
   PubMed Web of Science ®Google Scholar
• SAARINEN UM, COCCIA PF, GERSONSL, PEELEY R, CHEUNG NK: Eradication of neuroblastoma cells in vitro by monoclonal antibodies and complement: method for purging autologous, bone marrow. Cancer Res. (1985) 45:5969–5975.
   PubMed Web of Science ®Google Scholar
• CARLSEN NLT: How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br. Cancer (1990) 61:441–446.
   Google Scholar
• BRODEUR GM, NAKAGAWARA A: Molecular basis of clinical heterogeneity in neuroblastoma. Am .1. Pediatr: Hem. Oncol (1992) 14:111–116.
   Google Scholar
• TEFANY FJ, BARNETSON RS, HALLIDAY GM, McCARTHY SW, McCARTHY H: Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. Invest. Dermatol (1991) 97:197–202.
   PubMed Web of Science ®Google Scholar
• BAKER HW: Biologic control of cancer. Arch. Surg. (1986) 121:1237–1241.
   PubMed Web of Science ®Google Scholar
• PENN I: Cancers complicating organ transplantation. N Engl. J. Med. (1990) 323:1767–1769.
   PubMed Web of Science ®Google Scholar
• HORN L, HORN H: An immunologic approach to the treatment of cancer? Lancet (1971) 2:466–469.
   PubMed Web of Science ®Google Scholar
• ••Early ideas about the immunotherapy ofneoplasms.
   Google Scholar
• COLE WH: Efforts to explain spontaneous regression of cancer. Surg. Oncol (1981) 17:201–209.
   Web of Science ®Google Scholar
• ROSENBERG SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Important Adv. Oncol (1986):55–91.
   PubMedGoogle Scholar
• ••Early and basic description of the adoptivecellular immunotherapy of neoplasms.
   Google Scholar
• SINKOVICS JG: Oncogenes and growth factors. CRC Critical Rev. Immunol (1988) 8:217–298.
   Google Scholar
• ••Significant and detailed review article about, oncogenes and growth factors.
   Google Scholar
• CULLITON BJ: Fighting cancer with designer cells. Science (1989) 244:1430–1433.
   PubMed Web of Science ®Google Scholar
• ••Significant article about theirnmunomodulation of cytotoxic cells employed in antineoplastic therapy today.
   Google Scholar
• HERSEY P: Cellular therapy. CLIFF. Opin. Oncol (1993) 5:1049–1054.
   PubMedGoogle Scholar
• ROSENBERG SA, TERRY W: Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. (1977) 25: 323–388.
   PubMedGoogle Scholar
• ROSENBERG SA: Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat. Rep. (1984) 68:233–255.
   PubMedGoogle Scholar
• SONDEL PM, HANK JA, KOHLER PC et al.: Lymphokine activated killing as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes. Prog. Clin. Biol. Res. (1989) 288:151–160.
   PubMedGoogle Scholar
• KATANO M, NAGUMO F, KUBOTA E et al.: Autologous tumour-specific cytotoxic T cell clone established from tumour infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2 (rIL-2): activation by autologous tumour cell alone. Biotherapy (1993) 6:25–32.
   PubMedGoogle Scholar
• BODEY B, BODEY B JR, SIEGEL SE: Immunophenotypic characterization of infiltrating poly- and mononuclear cells in childhood brain tumors. Mod. Pathol (1995) 8:333–338.
   PubMed Web of Science ®Google Scholar
• BODEY B, BODEY B JR, SIEGEL SE, LUCK JV, KAISER HE: Immunophenotypic characterization of human primary and metastatic melanoma infiltrating autologous immunological effector cells. Anticancer Res. (1996) 16:3439–3446.
   PubMed Web of Science ®Google Scholar
• HAWKINS MJ: Interleukin-2 antitumor and effector cell response. Semin. Oncol (1993) 20\(Suppl. 052–59.
   Google Scholar
• MACCALI C, MORTARINI R, PARMIANI G, ANICHINI A: Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Inter. J. Cancer. (1994) 57:56–62.
   PubMed Web of Science ®Google Scholar
• SHI L, KAM CM, POWERS JC, AEBERSOLD R, GREENBERG AH: Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. Exp. Med. (1992) 176:1521–1529.
   PubMed Web of Science ®Google Scholar
• NAGATA S, GOLSTEIN P: The Fas death factor. Science (1995) 267:1449–1456.
   PubMed Web of Science ®Google Scholar
• KHAR A, PARSHASARADHI BVV, VARALAKSHMI CH, ALI MA, KUMARI AL: Natural killer cells as the effector which mediates in vivo apoptosis in AK-5 tumor cells. Cell. Immunol (1997) 177:86–92.
   PubMed Web of Science ®Google Scholar
• TRINCHIERI G: Biology of natural killer cells. Adv. Immunol (1989) 47:187–376.
   PubMed Web of Science ®Google Scholar
• ••Important review article about thebiological aspects of NK cells.
   Google Scholar
• FESUS L, DAVIES PJA, PIACENTINI M,: Apoptosis: molecular mechanism in programmed cell death. Eur. I Cell Biol. (1991) 56:170–177.
   PubMed Web of Science ®Google Scholar
• HOON DB, BOWKER RJ, COCHRAN Al: Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res. (1987) 47:1529–1533.
   PubMed Web of Science ®Google Scholar
• SHAW HM, McCARTHY SW, McCARTHY WH, THOMPSON JF, MILTON GW: Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology (1989) 15:257–265.
   PubMed Web of Science ®Google Scholar
• RESTIFO NP, KAWAKAMI Y, MARINCOLA F et al: Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. ./. Ipanunother: (1993) 14:182–190.
   PubMed Web of Science ®Google Scholar
• SCHRIER PI, BERNARDS R, VAESSEN RTMJ, HOUWELING A, VAN DER EB AJ: Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature (1983) 305:771–775.
   PubMed Web of Science ®Google Scholar
• ROONEY CM, ROWE M, WALLACE LE, RICKINSON AB: Epstein-Barr virus positive Burkitt's lymphoma cells not recognized by virus specificT-cell surveillance. Nature (1985) 317:629–631.
   PubMed Web of Science ®Google Scholar
• WEBER JS, KAY G, TANAKA K, ROSENBERG SA: Immunotherapy of a murine tumor with interleukin-2: increased sensitivity after MHC class I gene transfection. Exp. Med. (1987) 166:1716–1722.
   PubMed Web of Science ®Google Scholar
• TANAKA K, YOSHIOKA T, BIEBERICH, C, JAY G: Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Ann. Rev Immunol (1988) 6:359–380.
   PubMed Web of Science ®Google Scholar
• VUJANOVIC NL, NAGASHIMA S, HERBERMAN RB, WHITESIDE TL: Nonsecretory apoptotic killing by human NK cells. J. Immuna (1996) 157:1117–1126.
   PubMed Web of Science ®Google Scholar
• VUJANOVIC NL, BASSE P, HERBERMAN RB, WHITESIDE TL: Antitumor functions of natural killer cells and control of metastases. Methods (1996) 9:394–408.
   PubMedGoogle Scholar
• KRADIN RL, XIA W, PIKE M, BYERS HR, PINTO C: Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology (1996) 64:180–186.
   PubMed Web of Science ®Google Scholar
• BODEY B, BODEY B JR, KAISER HE: Dendritic, type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. In vivo (1997) 11:351–370.
   Google Scholar
• ••Neuroendocrine aspects of importantantigen presentation by DCs.
   Google Scholar
• UNDERWOOD JC: Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br. Cancer (1974) 30:538–548.
   Google Scholar
• •Early observations about the TILs.
   Google Scholar
• IOACHIM HL: The stromal reaction of tumors: an expression of immune surveillance. Natl. Cancer Inst. (1976) 57:465–475.
   Google Scholar
• RUITER DJ, BHAN AK, HARRIST TJ, SOBER AJ, MIHM MC JR: Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. Immunol. (1982) 129:2808–2815.
   Web of Science ®Google Scholar
• MIKHAIL GR, GORSULOWSKY DC: Spontaneous regression of metastatic malignant melanoma. Dermatol. Surg. Oncol. (1986) 12:497–500.
   Web of Science ®Google Scholar
• HERBERMAN RB, HOLDEN HT: Natural cell-mediated immunity. Adv. Cancer Res. (1978) 27:305–337.
   PubMedGoogle Scholar
• ••Important review about the natural cellmediated immunity by the original discoverer of NK cells.
   Google Scholar
• NOWELL P: The clonal evolution of tumor cell populations. Science (1976) 194:23–28.
   PubMed Web of Science ®Google Scholar
• NICOLSON GL: Tumor cell instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res. (1987) 47:1473–1487.
   PubMed Web of Science ®Google Scholar
• COROMINAS M, LEON J, KAMINO H, CRUZ-ALVAREZ M, NOVICK SC, PELLICER A: Oncogene involvement in tumor regression: H-ras activation in the rabbit keratoacanthoma model. Oncogene (1991) 6:645–651.
   PubMed Web of Science ®Google Scholar
• ALEXANDROW MG, MOSES HL: Transforming growth factor beta and cell cycle regulation. Cancer Res. (1995) 55:1452–1457.
   PubMed Web of Science ®Google Scholar
• KLEIN G: The approaching era of the tumor suppressor genes. Science (1987) 238:1539–1545.
   PubMed Web of Science ®Google Scholar
• BARBACID M: ras genes. Ann. Rev. Biochem. (1987) 56:779–827.
   PubMed Web of Science ®Google Scholar
• BOS JL: The ras gene family and human carcinogenesis,. Mutat Res. (1988) 195:255–271.
   PubMed Web of Science ®Google Scholar
• BODEY B, BODEY B JR, GROGER AM et al.: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res. (1997) 17:1319–1330.
   PubMed Web of Science ®Google Scholar
• HERCBERGS A, LEITH JT: Spontaneous remission of metastatic lung cancer following myxedema coma - an apoptosis-related phenomenon? Nati Cancer Inst. (1993) 85:1342–1343.
   Google Scholar
• BODEY B, BODEY B JR, HALL FL: Expression of transforming growth factor-beta type II receptors in the cells of the human thymic microenvironment during ontogenesis. In: Molecular Biology of Hematopoiesis (Vol. 5 ). Abraham NG, Asano S, Brittinger G, Maestroni GJM, Shadduck R (eds), Plenum Press, New York (1996):645–658.
   Google Scholar
• EAVES C, EAVES A: Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation M vitro. Blood Cells (1994) 20:83–95.
   PubMedGoogle Scholar
• NATHASON L: Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl. Cancer Inst. Monogr: (1976) 44:67–76.
   PubMedGoogle Scholar
• ••Early description of the cases of SR inmelanomas.
   Google Scholar
• BIRGE RE JENKS AL, DAVIS SK: Spontaneous remission in acute leukemia: report of a case complicated with eclampsia. JAMA (1949) 140:589–592.
   PubMed Web of Science ®Google Scholar
• CANTINI E, JAMES B: Acute myelogenous leukemia in pregnancy. South. Med. J. (1984) 77:1050–1052.
   PubMed Web of Science ®Google Scholar
• SMITHERS DW: Cancer of the breast and menopause. Clin. Radio]. (1952) 4:89–96.
   Google Scholar
• LEWISON EF: Spontaneous regression of breast cancer. Natl. Cancer Inst. Monogr: (1976) 44:23–26.
   PubMedGoogle Scholar
• ROSS MB, BUZDAR AU, HORTOBAGYI, GN, LUKEMAN JM: Spontaneous regression of breast carcinoma: follow-up report and literature review. Surg. Oncol. (1982) 19:22–24.
   Web of Science ®Google Scholar
• TAETLE R, GUITTARAD JP: Modulation of leukaemia blast colony growth by steroid hormones. Br. .1 Haemat (1982) 50:247–255.
   PubMed Web of Science ®Google Scholar
• FISHER RI, NEIFELD JP, LIPPMAN ME: Oestrogen receptors in human malignant, melanoma. Lancet (1976) 2:337–339.
   PubMed Web of Science ®Google Scholar
• PAPAC RJ, KIRKWOOD J: High dose tammdfen in malignant melanoma. Cancer Treat. Rep. (1983) 67:1049.
   PubMedGoogle Scholar
• WALKER MJ: Role of hormones and growth factors in melanomas. Semin. Oncol. (1988) 15:512–523.
   PubMed Web of Science ®Google Scholar
• JETTEN AM, JETTEN MER: Possible role of retinoic acid binding protein in retinoid stimulation of embryonal carcinoma cell differentiation. Nature (1979) 278:180–182.
   PubMed Web of Science ®Google Scholar
• TROWN PW, PALLERONI AV, BOHOSLAWES 0 et al.: Relationship between binding affinities to cellular retinoic acid-binding protein and in vivo and M vitro properties for 18 retinoids. Cancer Res. (1980) 40:212–220.
   Google Scholar
• JETTEN AM, DELUCA LM: Induction of differentiation of embryonal carcinoma cells by retinol: possible mechanisms. Biochem. Biophys. Res. Commun. (1983) 114:593–599.
   PubMed Web of Science ®Google Scholar
• EGLITIS MA, SHERMAN MI: Murine embryonal carcinoma cells differentiate M vitro in response to retinol. Exp. Cell Res. (1983) 146:289–296.
   PubMed Web of Science ®Google Scholar
• STRICKLAND S, BREITMAN TR, FRICKEL F, NURRENBACH A, HADICKE E, SPORN MB: Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells. Cancer Res. (1983) 43:5268–5272.
   PubMed Web of Science ®Google Scholar
• JETTEN AM: Induction of differentiation of embryonal carcinoma cells by retinoids. In: Retinoids and Cell Differentiation. Sherman MI (ed.), CRC Press, Boca Raton, USA (1986):105.
   Google Scholar
• JETTEN AM, ANDERSON K, DEAS MA et al.: New benzoic acid derivatives with retinoid activity: lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein. Cancer Res. (1987) 47:3523–3527.
   PubMed Web of Science ®Google Scholar
• GIGUERE V, ONG ES, SEGUI P, EVANS RM: Identification of a receptor for the morphogen retinoic acid. Nature (1987) 330:624–629.
   PubMed Web of Science ®Google Scholar
• PIERCE GB: Teratocarcinoma: model for a developmental concept of cancer. Curt Top. Dev. Biol. (1967) 2:223–246.
   PubMedGoogle Scholar
• Teratomas and Differentiation. Sherman MI, Softer D (eds), Academic Press, New York, (1975).
   Google Scholar
• MARTIN GR: Teratocarcinomas and mammalian embryogenesis. Science (1980) 209:768–776.
   PubMed Web of Science ®Google Scholar
• BOLANDE RP: Models and concepts derived from human teratogenesis and oncogenesis in early life. Histochem. Cytochem. (1984) 32:878–884.
   PubMed Web of Science ®Google Scholar
• ASTIGIANO S, SHERMAN MI, ABARZUA P: Regulation and patterns of endogenous and exogenous gene expression during differentiation of embryonal carcinoma cells. Envic Health Persp. (1989) 80:25–38.
   PubMed Web of Science ®Google Scholar
• STRICKLAND S, MAHDAVI V: The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell (1978) 15:393–403.
   PubMed Web of Science ®Google Scholar
• STRICKLAND S, SMITH KK, MAROTTI KR: Hormonal induction of differentiation in teratocarcinoma stem cells: generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell (1980) 21:347–355.
   PubMed Web of Science ®Google Scholar
• GROVER A, OSHIMA RG, ADAMSON ED: Epithelial layer formation in differentiating aggregates of F9 embryonal carcinoma cells.' Cell Biol. (1983) 96:1690–1696.
   PubMed Web of Science ®Google Scholar
• GROVER A, ADAMSON ED: Evidence for the existence of an early common biochemical pathway in the differentiation of F9 cells into visceral or parietal endoderm: modulation by cyclic AMP. Dev. Biol. (1986) 114:492–503.
   PubMed Web of Science ®Google Scholar
• HONG WK, WITTES RE, HAJDU ST, CVITKOVIC E, WHITMORE WF, GOLBEY RB: The evolution of mature teratoma from malignant testicular tumors. Cancer (1977) 40:2987–2992.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN SJ, SKEHAN P: Morphological differentiation of human choriocarcinoma cells induced by methotrexate. Cancer Res. (1979) 39:1960–1967.
   PubMed Web of Science ®Google Scholar
• HAAS D, ABLIN AR, MILLER C, ZOGER S, MATTHAY KK: Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer (1988) 62:818–825.
   PubMedGoogle Scholar
• CASTAIGNE S, CHOMIENNE C, DANIEL MT et al.: All transretinoic acid as differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 76:1704–1709.
   PubMed Web of Science ®Google Scholar
• KURIE JM, BOSL GJ, DMITROVSKY ED: The genetic and biologic aspects of treatment, response and resistance in male germ, cell cancer. Semin. Oncol (1992) 19:197–205.
   PubMed Web of Science ®Google Scholar
• STOLL BA: Spontaneous regression of cancer: new insights. Biotherapy (1992) 4:23–30.
   PubMedGoogle Scholar
• HELMLINGER G, NETTI PA, LICHTENBELD HC, MELDER RJ, JAIN RK: Solid stress inhibits the growth of multicellular tumor spheroids. Nat. Biotech. (1997) 15:778–783.
   PubMed Web of Science ®Google Scholar
• FUNG YC: Biomechanical aspects of growth and tissue engineering. In: Biomechanics, Motion, Dow, Stress, and Growth. Fung YC (ed.), Springer-Verlag, New York (1990):499–546.
   Google Scholar
• VAAGE J: Fibrosis in immune control of mammary-tumor growth. Int. .1. Cancer (1992) 51:325–328.
   PubMed Web of Science ®Google Scholar
• GARTNER MFRM, FEARNS C, WILSON EL, CAMPBELL JAH, DOWDLE EB: Unusual growth characteristics of human melanoma xenografts in the nude mouse: a model for desmoplasia, dormancy and progression. Br. J. Cancer(1992) 65:487–490.
   PubMed Web of Science ®Google Scholar
• YOUNG JS: The invasive growth of malignant tumours: an experimental interpretation based on elastic-jelly models. Pathol Bact. (1959) 77:321–326.
   PubMedGoogle Scholar
• EAVES G: The invasive growth of malignant tumours as a purely mechanical process. Pathol (1973) 109:233–237.
   Web of Science ®Google Scholar
• FALK P: Patterns of vasculature in two pairs of related fibrosarcomas in the rat and their relation to tumour responses to single large doses of radiation. Ear: J. Cancer (1978) 14:237–250.
   PubMed Web of Science ®Google Scholar
• FALK P: The vascular pattern of the spontaneous C3H mouse mammary carcinoma and its significance in radiation response and in hyperthermia. Ear: .1. Cancer (1980) 16:203–217.
   Google Scholar
• TOZER GM, LEWIS S, MICHALOWSKI, A, ABER V: The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br. J. Cancer (1990) 61:250–257.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Determinants of tumor blood flow: a review. Cancer Res. (1988) 48:2641–2658.
   PubMed Web of Science ®Google Scholar
• LI L, PRICE JE, FAN D, ZHANG RD, BUCANA CD, FIDLER IJ: Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. Nati Cancer, Inst. (1989) 81:1406–1412.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND RM: Cell and environment, interactions in tumor microregions: the multicell spheroid model. Science (1988) 240:177–184.
   PubMed Web of Science ®Google Scholar
• OLDHAM RK, LEWKO WM, GOOD RW et al.: Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC). In vivo (1994) 8:653–663.
   PubMedGoogle Scholar
• ROSENBERG SA, BLAESE RM, BRENNER MK et al.: Human gene marker/therapy clinical protocols. Hum. Gene The]: (2000) 11:919–979.
   PubMed Web of Science ®Google Scholar
• JAGER D, JAGER E, KNUTH A: Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. Clin. Pathol. (2001) 54:669-674. Comment in: Clin. Pathol. (2001) 54:675–676.
   Google Scholar
• ••Nice review of neoplasm-associatedantigens and their role in antigen specific antineoplastic immunotherapy.
   Google Scholar
• PIKE M, PETERS R, COZEN W et al.: Estrogen-progestin replacement therapy and endometrial cancer. Nati Cancer Inst. (1997) 89:1110–1116.
   PubMed Web of Science ®Google Scholar
• STEINBRECHNER UP, LISBONA R, HUANG SN, MISHKIN S: Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig. Dis. Sci. (1981) 26:1045–1050.
   PubMed Web of Science ®Google Scholar
• TAHARA H, SHIOZAKI H, KOBAYASHI K et al.: Phenotypic characteristics of tumour-infiltrating-lymphocytes in human oesophageal cancer tissues defined by quantitative two colour analysis with flow-cytometry. Virchows Arch. (1990) 416:329–334.
   Web of Science ®Google Scholar
• BELLDEGRUN A, KASID A, UPPENKAMP M, TOPALIAN SL, ROSENBERG SA: Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. Immunol. (1989) 142:4520–4526.
   Google Scholar
• MUUL LM, SPIESS PJ, DIRECTOR EP, ROSENBERG SA: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Innnunol. (1987) 101:171–181.
   Google Scholar
• SOMERS SS, GUILLOU PJ: Isolation and expansion of lymphocytes from gastrointestinal tumour tissue. Sorg. Oncol. (1993) 2:283–291.
   Web of Science ®Google Scholar
• BELLDEGRUN A, MUUL LM, ROSENBERG, SA: Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. (1988) 48:206–214.
   PubMed Web of Science ®Google Scholar
• YOSHIDA K, TACHIBANA T: Prevention, of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells. Cancer Immunol Immunother. (1993) 36:323–330.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann. Surg. (1988) 208:121–135.
   PubMed Web of Science ®Google Scholar
• PANELLI MC, BETTINOTTI MP, LALLY K et al.: A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J. Immunol (2000) 164:4382–4392.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: Progress in human tumour immunology and immunotherapy. Nature (2001) 411:380–384.
   PubMed Web of Science ®Google Scholar
• ••Important article about the new aspects ofantineoplastic immunotherapy.
   Google Scholar
• DUDLEY ME, WUNDERLICH J, NISHIMURA MI et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. .1 Immunother. (2001) 24:363–373.
   Google Scholar
• HARADA M, LI YF, EL-GAMIL M, OHNMACHT GA, ROSENBERG SA, ROBBINS PF: Melanoma-reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. Immunother,. (2001) 24:323–333.
   PubMed Web of Science ®Google Scholar
• RILEY JP, ROSENBERG SA, PARKHURST MR: Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. .1 Immunother. (2001) 24:212–220.
   Google Scholar
• RILEY JP, ROSENBERG SA, PARKHURST MR: Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. .1 Immunother. (2001) 24:212–220.
   Google Scholar
• HAAS GP, SOLOMON D, ROSENBERG SA: Tumor infiltrating lymphocytes from non-renal urological malignancies. Cancer Immunol Immunother. (1990) 30:342–350.
   PubMed Web of Science ®Google Scholar
• MIESCHER S, WHITESIDE TL, MORETTA L, VON FLIEDNER V: Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. Immunol. (1987) 138:4004–4011.
   Web of Science ®Google Scholar
• SCHILTZ PM, BEUTEL LD, NAYAK SK, DILLMAN RO: Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. Immunother. (1997) 20:377–386.
   PubMed Web of Science ®Google Scholar
• FREEDMAN RS, TOMASOVIC B, TEMPLIN S et al.: Large-scale expansion in interleukin-2 of tumor infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. .1 Immunol. Methods (1994) 167:145–160.
   Google Scholar
• FREEDMAN RS, EDWARDS CL, KAVANAGH JJ et al.: Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. .1. Immunother. (1994) 16:198–210.
   Google Scholar
• LEWKO WM, GOOD RW, BOWMAN D,, SMITH TL, OLDHAM RK: Growth of tumor derived activated T-cells for the treatment of cancer. Cancer Biother. (1994) 9:211–224.
   PubMedGoogle Scholar
• TOPALIAN SL, KASID A, ROSENBERG SA: Immunoselection of a human melanoma Resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. Immunol. (1990) 144:4487–4495.
   Google Scholar
• LIU K, ROSENBERG SA: Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. Immunol (2001) 167(11):6356–6365.
   Web of Science ®Google Scholar
• ••Employment of genetic engineering inmelanoma reactive cytotoxic cells.
   Google Scholar
• BEUN GD, VAN DE VELDE CJ, FEUREN GJ: T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition? Immunol. Today (1994) 15:11–15.
   Google Scholar
• DEMANET C, BRISSINCK J, LEO 0, MOSER M, THIELEMANS K: Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD 3) treatment of the BCL1 lymphoma. Cancer Res. (1994) 54:2973–2978.
   PubMed Web of Science ®Google Scholar
• THIBAULT C, NELSON H, CHAPOVL Al: Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab)2 bispecific antibodies. Int. .1 Cancer (1996) 67:232–237.
   Google Scholar
• FERRINI S, CAMBIAGGI A, SFORZINI S, et al: Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells. Cancer Detect. Prevent. (1993) 17:295–300.
   PubMedGoogle Scholar
• WEINER LM, HOLMES M, ADAMS GP, LACRETA F, WATTS P, GARCIA de PALAZZO I: A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. (1993) 53:94–100.
   PubMed Web of Science ®Google Scholar
• HOMBACH A, TILLMANN T, JENSEN M, et al.: Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Thl differentiation and recruitment of MHC-independent cytotoxicity. Clin. Exp. Immunol. (1997) 108:352–357.
   Google Scholar
• CHAPOVAL Al, NELSON H, THIBAULT C, PENNA C, DEAN P: Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application. Hematothec (1995) 4:571–577.
   PubMedGoogle Scholar
• CSOKA M, STRAUSS G, DEBATIN KM, MOLDENHAUER G: Activation of T, cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Leukemia (1996) 10: 1765-1772.
   Google Scholar
• DEMANET C, BRISSINCK J, De JON GE J, THIELEMANS K: Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood (1996) 87:4390–4398.
   PubMed Web of Science ®Google Scholar
• HAAS C, SCHIRRMACHER V: Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Cancer Immunol. Immunother. (1996) 43:190–194.
   PubMed Web of Science ®Google Scholar
• HOLLIGER P, BRISSINCK J, WILLIAMS RL, THIELEMANS K, WINTER G: Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng. (1996) 9:299–305.
   PubMedGoogle Scholar
• KROESEN BJ, WELLENBERG GJ, BAKKER A, HELFRICH W, THE TH, DE LEIJ L: The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity. Br. Cancer (1996) 73:721–727.
   Google Scholar
• KUWAHARA M, KUROKI M, ARAKAWA F et al.: A mouse/human- chimeric, bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Anticancer Res. (1996) 16:2661–2667.
   PubMed Web of Science ®Google Scholar
• MACK M, GRUBER R, SCHMIDT S, RIETHMULLER G, KUFER P: Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. Immunol (1997) 158:3965–3970.
   Web of Science ®Google Scholar
• RENNER C, HELD G, OHNESORGE S et al.: Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer Immunol Immunother. (1997) 44:70–76.
   PubMed Web of Science ®Google Scholar
• BLAESE RM, MULLEN CA, RAMSEY WJ: Strategies for gene therapy. Pathologie Biologie (1993) 41:672–676.
   PubMed Web of Science ®Google Scholar
• HWU P, ROSENBERG SA: The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detect. Prevent. (1994) 18:43–50.
   PubMedGoogle Scholar
• KAWAKAMI Y, ROSENBERG SA, LOTZE MT: Interleukin-4 promotes the growth of tumor infiltrating lymphocytes cytotoxic for human autologous melanoma. Exp. Med. (1988) 168:2183–2191.
   PubMed Web of Science ®Google Scholar
• KIM TS, COHEN EP: MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens. Cancer Immunol Immunother. (1994) 38:185–193.
   PubMed Web of Science ®Google Scholar
• ABDEL-WAHAB Z, WELTZ C, HESTER D et al.: Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer (1997) 80:401–412.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM, PARDOLL DM: Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods (1997) 12:143–153.
   PubMed Web of Science ®Google Scholar
• FEARON ER, PARDOLL DM, ITAYA T et al.: IL-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell (1990) 60:387–403.
   PubMedGoogle Scholar
• GOLUMBEK PT, LAZENBY AJ, LEVITSKY HI et al.: Treatment of established, renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 254:713–716.
   PubMed Web of Science ®Google Scholar
• LIPSHY KA, KOSTUCHENKO PJ, HAMAD GG, BLAND CE, BARRETT SK, BEAR HD: Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma. Ann. Surg. Oncol (1997) 4:334–341.
   PubMed Web of Science ®Google Scholar
• ARUGA E, ARUGA A, ARCA MJ et al: Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin 12, or GM-CSF. Cancer Gene Ther. (1997) 4:157–166.
   PubMed Web of Science ®Google Scholar
• ARIENTI F, SULE-SUSO J, BELLI F et al.: Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther: (1996) 7:1955–1963.
   Google Scholar
• BASKAR S: Gene-modified tumor cells as cellular vaccine. Cancer Immunol Immunother: (1996) 43:165–173.
   PubMed Web of Science ®Google Scholar
• DAR MM, ABDEL-WAHAB Z, VERVAERT CE, DARROW T, BARBER J, SEIGLER HF: Immunological memory induced by genetically transduced tumor cells. Ann. Surg. Oncol (1996) 3:247–254.
   PubMed Web of Science ®Google Scholar
• De WIT D, FLEMMING CL, HARRIS JD et al.: IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL). Clin. Exp. Immunol (1996) 105:353–359.
   PubMed Web of Science ®Google Scholar
• DUNUSSI-JOANNOPOULOS K, WEINSTEIN HJ et al.: Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood (1996) 87:2938–2946.
   PubMed Web of Science ®Google Scholar
• KNIGHT BC, SOUBERBIELLE BE, RIZZARDI GP, BALL SE, DALGLEISH AG: Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res. (1996) 6:299–306.
   PubMed Web of Science ®Google Scholar
• LEVITSKY HI, MONTGOMERY J, AHMADZADEH M et al.: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. Immunol (1996) 156:3858–3865.
   Web of Science ®Google Scholar
• MULE JJ, CUSTER M, AVERBOOK Bet al.: RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in, vivo: role of immune cell subpopulations,. Hum. Gene Ther: (1996) 7:1545–1553.
   Google Scholar
• OHNO K, YOSHIZAWA H, TSUKADA H et al.: Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells. I Immunol (1996) 156:3875–3881.
   PubMed Web of Science ®Google Scholar
• TUNG C, FEDEROFF HJ, BROWNLEE M, et al.: Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum. Gene Ther: (1996) 7:2217–2224.
   Google Scholar
• WAKIMOTO H, ABE J, TSUNODA R, AOYAGI M, HIRAKAWA K, HAMADA H: Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. (1996) 56:1828–1833.
   PubMed Web of Science ®Google Scholar
• GAKEN JA, HOLLINGSWORTH SJ, HIRST WJ et al.: Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4*-mediated rejection of established tumors. Hum. Gene Ther. (1997) 8:477–488.
   Google Scholar
• LEE CT, WU S, CIERNIK IF et al.: Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther: (1997) 8:187–193.
   PubMed Web of Science ®Google Scholar
• SCHMIDT W, MAASS G, BUSCHLE M et al.: Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferrinfection (AVET). Gene (1997) 190:211–216.
   PubMed Web of Science ®Google Scholar
• NAIR SK, SNYDER D, ROUSE BT, GILBOA E: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer (1997) 70:706–715.
   PubMed Web of Science ®Google Scholar
• SINKOVICS JG, HORVATH J: New developments in the virus therapy of cancer: a historical review. Intervirology (1993) 36:193–214.
   PubMed Web of Science ®Google Scholar
• ••Detailed description of new aspects ofviral antineoplastic therapy.
   Google Scholar
• KASID A, MORECKI S, AEBERSOLD P et al.: Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc. Natl. Acad. Sci. USA (1990) 87:473–477.
   PubMed Web of Science ®Google Scholar
• ••Relatively early experiments on gene transfer, possibilities employing TILs.
   Google Scholar
• ABE J, WAKIMOTO H, TSUNODA R et al.: In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction. Biochem. Biophys. Res. Commun. (1996) 218:164–170.
   PubMed Web of Science ®Google Scholar
• NORDON RE, SCHINDHELM K: Ex vivo manipulation of cell subsets for cell therapies. Artil Organs (1996) 20:396–402.
   PubMed Web of Science ®Google Scholar
• •Significant summary of ex vivo handling of TIL subpopulations.
   Google Scholar
• TADA M, SAWAMURA Y, SAKUMA Set al.: Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas. Cancer Immunol. Immunother. (1993) 36:251–259.
   Google Scholar
• MORITZ D, GRONER B: A spacer region between the single chain antibody-and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther. (1995) 2:539–546.
   PubMed Web of Science ®Google Scholar